Q1 Earnings Estimate for HALO Issued By Leerink Partnrs

Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Halozyme Therapeutics in a research report issued to clients and investors on Sunday, January 12th. Leerink Partnrs analyst D. Risinger expects that the biopharmaceutical company will post earnings per share of $0.93 for the quarter. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $3.80 per share. Leerink Partnrs also issued estimates for Halozyme Therapeutics’ Q2 2025 earnings at $1.04 EPS, Q3 2025 earnings at $1.41 EPS and FY2029 earnings at $8.16 EPS.

Several other research firms also recently issued reports on HALO. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Friday, October 18th. JPMorgan Chase & Co. cut shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the company from $52.00 to $57.00 in a research report on Thursday, September 19th. HC Wainwright raised their price target on shares of Halozyme Therapeutics from $68.00 to $70.00 and gave the company a “buy” rating in a research note on Friday. Piper Sandler boosted their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a “neutral” rating in a research note on Friday. Finally, Wells Fargo & Company lowered their target price on Halozyme Therapeutics from $62.00 to $57.00 and set an “equal weight” rating for the company in a research report on Monday. Four research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $60.89.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $54.14 on Tuesday. The company has a quick ratio of 9.15, a current ratio of 10.36 and a debt-to-equity ratio of 3.32. The stock has a market cap of $6.89 billion, a PE ratio of 17.93, a PEG ratio of 0.44 and a beta of 1.24. Halozyme Therapeutics has a 12-month low of $33.15 and a 12-month high of $65.53. The business has a 50-day simple moving average of $50.14 and a two-hundred day simple moving average of $54.03.

Insiders Place Their Bets

In other Halozyme Therapeutics news, SVP Michael J. Labarre sold 10,000 shares of the firm’s stock in a transaction on Wednesday, October 16th. The shares were sold at an average price of $53.26, for a total value of $532,600.00. Following the completion of the sale, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $9,254,244.56. This trade represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Halozyme Therapeutics

Several large investors have recently made changes to their positions in the company. Skandinaviska Enskilda Banken AB publ bought a new stake in Halozyme Therapeutics during the 2nd quarter valued at $49,000. GAMMA Investing LLC increased its position in shares of Halozyme Therapeutics by 67.7% during the third quarter. GAMMA Investing LLC now owns 867 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 350 shares in the last quarter. Toth Financial Advisory Corp acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth about $57,000. FSC Wealth Advisors LLC bought a new position in Halozyme Therapeutics in the 3rd quarter valued at about $65,000. Finally, Park Place Capital Corp boosted its stake in Halozyme Therapeutics by 828.1% during the 3rd quarter. Park Place Capital Corp now owns 1,355 shares of the biopharmaceutical company’s stock valued at $78,000 after purchasing an additional 1,209 shares during the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.